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and outcome of patients with b thalassemia major (TM) who
was HCV sero-positive (HCV+) prior to an allogeneic stem cell
transplant (SCT). From October, 1991 to June, 2012, 370 SCT
were done for TM at our center. Themedian agewas 7.5 years
(range: 2-24) and therewere 232 (62.87%)males. 209 (56.5%)
belonged to Lucarelli Class III. There were 44 (11.9%) cases
who were HCV+, 6 (1.6%) who were HBsAg positive and 350
(94.6%) who were CMV sero-positive at the time of pre-
transplant screening.
HCV+ cases were signiﬁcantly older (P ¼ .000) and had
a signiﬁcantly larger liver size (P ¼ .001). There were signif-
icantly more number of HCV+ cases who were Lucarelli Class
III (84% Vs. 52.8%; P ¼ .000). The number of graft rejections
was signiﬁcantly higher in the HCV+ group (22.7% Vs. 10.4%;
P ¼ .025) while the treatment related mortality was
comparable between the two groups. It is well recognized
that patients with TM are at a high risk of developing sinu-
soidal obstruction syndrome (SOS) post SCT. In this series,
165 (44.6%) patients developed SOS. HCV+ cases did not have
a signiﬁcantly higher incidence of SOS compared to those
that were HCV negative (47.7% Vs. 44.3%; P ¼ .747). Among
the 15 (34%) of HCV+ cases that died, the major contributory
cause of death was infection (40%), graft failure (20%) and
SOS (20%). The overall and event free survival among those
that were HCV+ve Vs. those that were negative was
63.78.1% Vs. 752.5% and 47.48.1% Vs. 702.7%; P-val-
ue¼0.158 and 0.019 respectively. On a univariate cox
regression analysis, HCV+ had an adverse impact on EFS
(RR¼1.710; 95%CI 1.066-1.744; P ¼ .026). However, on
a forward stepwise multivariate analysis after adjusting for
conventional risk factors HCV+ status did not confer an
independent adverse risk factor. Of the 29 HCV+ patients
who are surviving, at a median follow up of 25 months, none
have had progression to chronic liver disease. 20 (69%) had
a normal liver function test at last follow up while only 3
have had HCV directed therapy post transplant.
From August, 2009 at our center we have been using
a treosulfan based conditioning regimen for our Class III
patients. Among the 44 HCV+ patients 10 were conditioned
with this regimen. This regimen was well tolerated with
100% engraftment. Two patients died, one due to sepsis and
the other to GVHD. This compared favorably with the
historical control of HCV+ cases conditioned with a conven-
tional busulfan based regimen.
In conclusion HCV+ status is a surrogate risk factor for
other adverse risk factors such as older age, increased liver
size and inadequate medical therapy prior to SCT. After
adjusting for such risk factors HCV+ cases with TM under-
going an allogeneic SCT transplant have comparable
outcomes to HCV negative cases. Use of a treosulfan based
regimen is well tolerated in the HCV+ group and could
potentially improve the outcome in this high risk group.97
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Juvenile myelomonocytic leukemia (JMML) is a rare and
aggressive childhood haematological malignant disorder.
Allogeneic HSCT is the only proven curative therapy. This
study reports more than 20 years (1986-2011) of French
experience in HSCT for children with JMML.
Outcome of 107 HSCT (91 children) performed between
March 1986 and November 2011 in 18 French centres was
retrospectively studied. Overall Survival (OS), Non Relapse
Mortality (NRM), Graft Versus Host Disease (GVHD) and
relapse cumulative incidences were analyzed per patient
from the ﬁrst transplantation. Multivariate analyses were
performed to assess risk factors. Statistical analyses were
carried out according to guidelines of European group for
Blood and Marrow Transplantation (EBMT).
Ninety-one children (58males), median age 1.4 yrs (range
0.0-15,7 yrs) with JMML underwent 107 allogeneic HSCT (14
second graft and a third one). The median follow-up was 47
months (1-166). At 72 months, OS was 59% (95% CI: 47-74).
Cumulative incidence of aGVHDwas 48% (95% CI: 37-58). The
6-year cumulative incidence of relapse and NRM was 34%
(95% CI: 23-44) and 21% (95% CI: 13-32), respectively. The
median delay of relapse was 80 days (range 15-1096). In
multivariate analysis, age at HSCT older than 2 years, female
donor tomale recipient sex-mismatch, matched unrelated or
mismatched non cord donor, total body irradiation and no
serotherapy in conditioning regimen predicted poorer
outcomes. Age at HSCT older than 2 years was an increased
risk of relapse whereas Busulfan/Cyclophosphamide/
Melphalan conditioning regimen was a decreased risk.
Serotherapy was associated with a decreased risk of NRM.
Age at HSCT older than 2 years and male recipient were
associated with higher probability of dying of NRM causes.
Our results show that allogeneic HSCT may cure approx-
imately 60% of patients with JMML and are similar to best
results published by other groups. Relapse represents the
main cause of treatment failure and a second HSCT should be
proposed. Novel strategies to decrease the risk of relapse are
needed.98
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The presence of acute leukemia or advanced myelodys-
plastic syndrome (MDS with 5% blasts or more) in Fanconi
Anemia (FA) patients is associated with very poor prognosis.
The experience of hematopoietic cell transplantation (HCT)
in these patients is limited, and the question of pre-trans-
plant chemotherapy remains. We report 21 FA patients with
acute myeloid leukemia, acute lymphoblastic leukemia, or
advanced MDS who underwent HCT at the University of
Minnesota from 1988-2009. 6 patients had biallelic BRCA2
mutations (29%). Median age at transplant was 15.5 years
(range 1.1-48.5). 7 patients (33%) received chemotherapy
before HCT, with 4 achieving complete remission. HCT
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either total body irradiation or Busulfan, with the addition of
Fludarabine in 13 patients (62%). In vivo T cell depletion with
Anti-Thymocyte Globulin was performed in 18 patients
(85%), and 11 donor grafts underwent ex vivo T cell depletion
(52%). Donor source included HLA-matched sibling (n¼3),
mismatched related donor (n¼1), unrelated marrow (n¼12)
and unrelated cord blood (n¼5). 58% of unrelated donors had
at least 1 HLA mismatch. Neutrophil engraftment for the
entire cohort was 90%, and 100% for those patients that
received Fludarabine. The incidence of acute GVHD was 19%
for the entire cohort. 5 year Overall Survival (OS) was 32%,
with a relapse rate of 20% (Figure). Of the patients that
received Fludarabine, 5 year OS was 38% with a relapse rate
of 30%. For the patients with biallelic BRCA2 mutation, 5 year
OS was 33% with a relapse rate of 50%
Our study provides evidence for use of HCT with a Flu-
darabine containing regimen for FA patients with acute
leukemia or advanced MDS, who would otherwise have
a dismal prognosis. The role of pre-HCT chemotherapy
remains unclear, and requires further investigation. BRCA2
patients are a unique subset of FA patients and require
tailored therapy to optimize HCT outcomes.
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To identify possible dose related toxicities of treosulfan
containing regimen and determine the incidence of
engraftment, treatment related mortality (TRM), overall
survival (OS) and event free survival (EFS) we explored 616
patients (pts) below 18 years who underwent HSCT between
January 2005 and July 2010 for malignant (n¼ 270, 43%) ornon malignant disease (n ¼ 356, 57%). To investigate
a potential non-linear association between dose and
outcome, fractional polynomials were used.533 pts under-
went allogeneic, 93 autologous HSCT. 513 (83%) pts received
a treosulfan-based conditioning regimen during their ﬁrst
HSCT. 124 (20%) had a matched sibling donor (MSD). The
stem cell source was bone marrow (BM) in 274 pts (44%) and
peripheral blood in 264 pts (42%).In the group of pts with
allogeneic HSCT, 41 were below the age of 6 months and 65
between 6-months and 1 year. 314 were between 1 and 12
years and 101 above 12 years. For allogeneic HSCT, the
median treosulfan dose was 42 g/msq (12-46). 24 pts (5%)
received less then 33 g/msq. 153 pts (29%) received between
33 and 39 g/msq. The majority of pts received a treosulfan
dose between 39 and 45 g/msq.
Results: There is no signiﬁcant correlation of the time to ANC
> 0.5x10e9/L with age and treosulfan-dose. Primary graft
failure occurred in 2% of cases with no signiﬁcant correlation
with age, treosulfan dose and underlying disease in uni- and
multivariate analysis. Acute graft-versus-host disease
(GvHD) of grade III-IV occurred in 10% of the patients and the
rate of limited and extended chronic GvHD was 13% and 6%,
respectively. The most common grade 3 or 4 toxicities were
diarrhoea (24%), stomatitis (22%), and SGOT elevation (25%).
Veno-occlusive disease was described in 5% of all pts. There
was a signiﬁcant association between age and VOD-inci-
dence, with higher VOD-rates in children below the age of
0.5 years (12%), that are exclusively children with non-
malignant diseases. Treosulfan-dose has no signiﬁcant
impact on VOD and GVHD in both univariate and multivar-
iate analysis. There is a border-line signiﬁcant impact of age
on overall survival. The 3-years pOS in children below 6
months, between 6 months and 1 year between 1-12 years
and > 12 years is 75%, 84%, 70% and 60%, respectively. This
difference is mainly caused by a difference in disease related
mortality (DRM). TRM is not signiﬁcantly different in the
different age groups. With respect to dose, we did not ﬁnd
a signiﬁcant impact on overall survival, neither in univariate
nor in adjusted analysis. However, therewas a better OS after
ﬁrst HSCT (0,74%) compared to second or third HSCT (0,51%),
P < .001.
Conclusion: These results emphasise the low toxicity proﬁle
of treosulfan, even in heavily pre-treated children and
adolescents and in patients undergoing a second HSCT. It was
shown that treosulfan is highly efﬁcient to enable engraft-
ment without increasing the risk for severe acute or chronic
GVHD.100
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Background: Myeloablative conditioning with busulfan and
cyclophosphamide (200 mg/kg) (Bu/CY) followed by HLA-
